# Asia Pacific Diabetes Pen Market

> Asia Pacific Diabetes Pen Market Research Report, by Product (Insulin Pens and Insulin Pen Needle), by Usage (Reusable Pens and Disposable Pens), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Sales, and Diabetes Clinics), by End User (Hospital, clinics and Others) and by region (India, Japan, China, Australia, Republic of Korea and Rest of Asia Pacific), Forecast to 2035

- **Forecast Period:** 2025-2035
- **CAGR:** 6.2%
- **2023:** $ 0.84 Billion
- **2024:** $ 0.88 Billion
- **2035:** $ 1.71 Billion
- **Key Players:** Roche Diagnostics, AstraZeneca plc., Johnson & Johnson, Abbott Laboratories, Biocon Ltd., Dexcom, Inc. (U.S.), Becton-Dickinson, Owen Mumford Ltd., Jiangsu Delfu Co., Novo Nordisk A/S, Ypsomed AG, Medtronic plc, Tandem Diabetes Care, Inc., Eli Lilly and Company, Sanofi S.A., Wockhardt Ltd.

**Report ID:** MRFR/MED/0194-HCR · **Pages:** 85 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/asia-pacific-diabetes-pen-market-637

---

## Market Summary

## **Asia Pacific Diabetes Pen Market Overview**

Asia Pacific Diabetes Pen Market Size was valued at USD 0.84 Billion in 2023. The Asia Pacific Diabetes Pen industry is projected to grow from USD 0.88 Billion in 2024 to USD 1.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.01% during the forecast period (2024 - 2032). Diabetes is the metabolic disease where there is increase in blood sugar level. Increase in blood sugar level is due less or no insulin secretion by body. Diabetes is now a days becoming a major problem in many countries.

Increasing prevalence of diabetes, government initiatives are the major driving factor for the market. Introduction of diabetic pen has help diabetic patient to administer insulin at their home itself. Asia Pacific is the fastest growing market for the diabetic pen. India and China has the major share of the market. 

**Study Objectives Asia Pacific Diabetes Pen Market Research Report**

**Figure 1:- Market Synopsis of Diabetes Pen Market by Devices, 2016 (%):  **

### **Key Players for Asia Pacific Diabetes Pen Market **

Roche Diagnostics, AstraZeneca plc., Johnson & Johnson, Abbott Laboratories, Biocon Ltd., Dexcom, Inc. (U.S.), Becton-Dickinson, Owen Mumford Ltd., Jiangsu Delfu Co., Novo Nordisk A/S, Ypsomed AG, [**Medtronic plc**](https://news.medtronic.com/Medtronic-launches-first-Smart-MDI-system-in-Europe-for-people-who-manage-their-diabetes-with-multiple-insulin-injections), and Tandem Diabetes Care, Inc. [**Eli Lilly and Company**](https://investor.lilly.com/news-releases/news-release-details/lilly-collaborates-internationally-leading-diabetes-technology), Sanofi S.A., and Wockhardt Ltd. 

## **Asia Pacific Diabetes Pen Market Segmentation**

## **Asia Pacific Diabetes Pen Market Regional Analysis **

On regional basis Asia Pacific is segmented into India, Japan, China, Australia, Republic of Korea and Rest of Asia Pacific. Asia Pacific is the fastest growing market in the world due to increase in the diabetic population and new research and development in the field of diabetic devices. India and China is the most populated countries where there is the major chances of increasing the diabetic population. Total diabetic population of India and China in 2012 is 61 million and 90 million respectively.

The report for Asia Pacific Diabetes Pen market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry.

The report also gives a broad study of the different markets segments and regions. 

### **Asia Pacific Diabetes Pen Market Intended Audience**

## Report Scope

| Attribute/Metric | Details |
| --- | --- |
| Market Size 2023 | 0.84 (USD Billion) |
| Market Size 2024 | 23.88 (USD Billion) |
| Market Size 2032 | 1.56 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 3.01 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
|   Geographies Covered |   North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
|   Key Vendors |  Roche Diagnostics, AstraZeneca plc., Johnson & Johnson, Abbott Laboratories, Biocon Ltd., Dexcom, Inc. (U.S.), Becton-Dickinson, Owen Mumford Ltd., Jiangsu Delfu Co., Novo Nordisk A/S, Ypsomed AG, Medtronic plc, and Tandem Diabetes Care, Inc. Eli Lilly and Company, Sanofi S.A., and Wockhardt Ltd |
|   Key Market Opportunities |  Diabetes is the metabolic disease where there is increase in blood sugar level |
|   Key Market Drivers | Increasing prevalence of diabetes, government initiatives are the major driving factor for the market |

---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/asia-pacific-diabetes-pen-market-637*